Table 1. Serum chromogranin A (CgA, IU/L) and proportion of abnormal results in patients with different neuroendocrine tumors (NETs) and related tumors.
| NET | n | Newly diagnosed | n | Follow-up | ||
|---|---|---|---|---|---|---|
| Mean ± SD Median (range) |
Proportion of abnormal | Mean ± SD Median (range) |
Proportion of abnormal | |||
| Carcinoid | 5 | 260.0 ± 237.9 262 (50–466) |
5/5 | 24 | 100.0 ± 140.9 14 (2–466) |
12/24 |
| Pheochromocytoma | 3 | 266.0 ± 80.6 266 (209–323) |
3/3 | 9 | 96.0 ± 114.0 44 (8–300) |
6/9 |
| Paraganglioma | 0 | - | - | 7 | 165.0 ± 338.0 21 (2–466) |
2/7 |
| Pancreatic NET | 5 | 360.0 ± 183.2 443 (87–466) |
5/5 | 3 | 159.0 ± 153.0 67 (26.9–435) |
3/3 |
| Adrenal adenoma | 7 | 106.0 ± 119.0 106 (27–309) |
7/7 | 2 | 74.0 ± 110.0 111 (10–201) |
1/2 |
| Prostate carcinoma | 2 | 34.0 ± 8.5 34 (28–40) |
2/2 | 0 | - | - |
| GI NET | 2 | 262.5 ± 287.8 262 (59–466) |
2/2 | 0 | - | - |
| Medullary thyroid Carcinoma | 1 | 51 | 1/1 | 1 | 89 | 1/1 |
| Shwannoma | 1 | 153 | 1/1 | 0 | - | - |
| Small cell carcinoma | 2 | 60.0 ± 18.3 60 (47–73) |
2/2 | 3 | 15.0 ± 11.0 16 (4–27) |
1/3 |
| Parathyroid adenoma | 2 | 569.0 ± 243.9 285 (112–457) |
2/2 | 5 | 28.7 ± 4.5 29 (24–33) |
2/5 |
| Pituitary macroadenoma | 8 | 13.0 ± 11.0 14 (2–32) |
2/8 | 2 | 13.5 ± 12.0 13.5 (5–22) |
0/2 |
| Inulinoma | 0 | - | - | 1 | 17 | 0/1 |
| Total | 38 | - | 32/38 | 57 | - | 28/57 |
Data presented as mean±standard deviation (SD), median (range), and proportion of change compared with assay cut-off of 22 IU/L. GI: gastrointestinal.